Literature DB >> 27867601

Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer.

Martin Metzenmacher1, Daniel C Christoph1.   

Abstract

Entities:  

Year:  2016        PMID： 27867601      PMCID： PMC5107548          DOI： 10.21037/jtd.2016.10.26

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

2.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

3.  Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Authors:  Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  Lancet Oncol       Date:  2012-02-16       Impact factor: 41.316

4.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

5.  5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation.

Authors:  Mathias Füller; Miriam Klein; Eva Schmidt; Christian Rohde; Stefanie Göllner; Isabell Schulze; Jiang Qianli; Wolfgang E Berdel; Bayram Edemir; Carsten Müller-Tidow; Petra Tschanter
Journal:  Int J Oncol       Date:  2014-12-10       Impact factor: 5.650

6.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

Review 7.  Epigenetics in non-small cell lung cancer: from basics to therapeutics.

Authors:  Junaid Ansari; Rodney E Shackelford; Hazem El-Osta
Journal:  Transl Lung Cancer Res       Date:  2016-04

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 9.  Clinical perspective of afatinib in non-small cell lung cancer.

Authors:  Xiaofeng Chen; Quan Zhu; Lingjun Zhu; Dong Pei; Yiqian Liu; Yongmei Yin; Martin Schuler; Yongqian Shu
Journal:  Lung Cancer       Date:  2013-05-10       Impact factor: 5.705

10.  Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Authors:  John Wrangle; Wei Wang; Alexander Koch; Hariharan Easwaran; Helai P Mohammad; Frank Vendetti; Wim Vancriekinge; Timothy Demeyer; Zhengzong Du; Princy Parsana; Kristen Rodgers; Ray-Whay Yen; Cynthia A Zahnow; Janis M Taube; Julie R Brahmer; Scott S Tykodi; Keith Easton; Richard D Carvajal; Peter A Jones; Peter W Laird; Daniel J Weisenberger; Salina Tsai; Rosalyn A Juergens; Suzanne L Topalian; Charles M Rudin; Malcolm V Brock; Drew Pardoll; Stephen B Baylin
Journal:  Oncotarget       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.